Neogen falls 2.3% after quarterly results and FDA warning weigh on the stock

What happened

Neogen (NEOG) fell 2.3% on October 7, 2026, after reporting fiscal 2027 first-quarter results that beat estimates and as an FDA warning tied to a veterinary product drew scrutiny. Trading volume was 2.7 times its 20-day average. The stock opened 5.4% above the previous close and finished the session at a closing price of $11.68. The S&P 500 fell 0.2% and the Healthcare sector median fell 0.4%, leaving the stock 1.9 percentage points worse than the sector median on the day.

How big was the move

The day's decline amounted to 0.6 times a typical daily move for this stock, a smaller-than-usual reaction given the mixed news. Volume at 2.7 times its 20-day average signaled heavier trading and underscored investor attention. Over the last five sessions the stock fell 8.8%, while the S&P 500 over five sessions rose 2.0%, underlining that Neogen's weakness was largely company-specific because of the results and the regulatory notice.

The technical picture

Technically, the stock traded 8.4% below its 20-day moving average and 3.3% below its 50-day moving average, while it remained 16.0% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 208 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) was 42, in a neutral range between 30 and 70. The stock was 18.1% below its 52-week high.

Shorter-term measures show mixed momentum. It fell 1.8% over one month but rose 19.8% over three months and 107.5% over one year, leaving it 91.7 percentage points ahead of the S&P 500 for the year. Volatility was 60% annualized over 60 days, higher than 84% of its own readings over five years, indicating more pronounced price swings than typical for the company.

Fundamentals and valuation

For the four quarters through August 31, 2026, revenue totaled $884.0 million, a decline of 0.3% from a year earlier. Gross margin improved to 47.4% from 41.1% a year earlier, while operating margin was 0.8% compared with 0.0% a year earlier. Diluted earnings per share for that period were $-0.25, and free-cash-flow margin was 5.6%.

Those figures present a mixed picture. Top-line sales were essentially flat year on year, but improving gross margins and a small positive operating margin point to better cost control or a shift in product mix. Return on invested capital was 0.6%. Share count over one year increased by 0.5%.

The balance sheet showed net debt of 5.7 times EBITDA, a sizable leverage metric that highlights risk and cash-generation pressure. Valuation measures show a price to forward earnings of 37.7 times expected earnings and a free-cash-flow yield of 1.9%.

PromtFinance scores ranked the company 73 for Value (Positive) and 79 for Momentum (Positive), while Growth, Quality and Stability scored 37, 40 and 33 respectively, indicating a stretched valuation alongside strong recent price momentum.

Earnings and analyst expectations

Neogen reported on October 6, 2026, earnings per share of $0.08 against $0.05 expected, 50.0% above estimates, according to Business Wire and GlobeNewsWire. That marked five consecutive quarters beating estimates. Management said the quarter reflected improved commercial execution, strength in food safety and animal safety product lines, and progress on the Petrifilm manufacturing transition. Reported fiscal 2027 first-quarter revenue was $222.8 million and core growth was 8.1%.

Average surprise over the last four reports was 69.2% above estimates, and the typical two-day reaction after recent reports was that the stock rose 3.7%. Despite that pattern, a regulatory headwind weighed on trading. An FDA warning and recall involving Neogen Vet's HYCOAT product was linked to fungal contamination and reports of at least 20 horse deaths. The notice prompted an investigation and coincided with a roughly 7% earlier drop in the stock, according to GuruFocus and PRNewsWire. That sequence helps explain why the stock traded down on a day of better-than-expected earnings.

Analysts maintain a consensus rating of Buy, with a consensus price target of $13.50, which is 15.6% above the closing price. Eleven analysts cover the stock and 45% of the ratings are Buy or similar. The next report is scheduled for January 14, 2027.

What to watch

• October 6, 2026: reported fiscal 2027 first-quarter revenue of $222.8 million and core growth of 8.1%, with quarterly earnings of $0.08 per share that beat the Zacks Consensus Estimate of $0.05.
• FDA warning and recall tied to Neogen Vet's HYCOAT product, linked to reports of at least 20 horse deaths and prompting an investigation notice.
• Net debt of 5.7 times EBITDA as reported for the four quarters through August 31, 2026.
• Consensus price target of $13.50, 15.6% above the closing price, with 11 analysts covering the stock.
• Next earnings report due January 14, 2027.